• If you are wondering whether Omnicell's current share price still reflects good value or if most of the opportunity is already priced in, the starting point is understanding how its valuation stacks up across several methods.
• Over the past year, the stock is up 63.6%, with a 3.6% gain over the last week and 18.3% over the past month, even though the year to date return is slightly down at 0.9% and longer term 3 year and 5 year returns are lower at 38.8% and 67.7% respectively.
• These price moves come as investors continue to reassess Omnicell's long term prospects, with recent coverage focusing on its position in healthcare technology and how its products fit into hospital automation and medication management trends. While shorter term sentiment can shift quickly, this context helps explain why the stock has attracted renewed attention.
• On Simply Wall St's 6 point valuation checklist, Omnicell scores a 2 out of 6, so the next sections will walk through how different models assess the stock's value and then finish with a broader way to think about valuation that goes beyond any single metric.

Omnicell scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Omnicell Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a stock could be worth by projecting the company’s future cash flows and discounting them back to today’s value. It focuses on what cash the business might generate for shareholders rather than only looking at earnings multiples.

For Omnicell, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $95.6 million. Analysts provide cash flow estimates out to 2030, with Simply Wall St extending the projections beyond the explicit analyst period. In this model, projected free cash flow in 2030 is $106.8 million, with annual figures between 2026 and 2035 discounted back to today to reflect risk and the time value of money.

Bringing these projected cash flows back to today gives an estimated intrinsic value of $54.17 per share. Compared with the current share price, this implies Omnicell is trading at a 17.4% discount, which suggests the stock may be undervalued under this DCF framework.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Omnicell is undervalued by 17.4%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Omnicell Price vs Earnings

For profitable companies, the P/E ratio is a useful way to relate what you pay for each share to the earnings that the business is currently generating. It gives you a quick sense of how many dollars investors are willing to pay for one dollar of earnings.

What counts as a “normal” P/E depends a lot on how fast earnings are expected to grow and how risky those earnings are. Higher expected growth and lower perceived risk often go with higher P/E ratios, while slower or more uncertain earnings usually line up with lower multiples.

Omnicell’s current P/E is 99.54x, compared with the Medical Equipment industry average of about 24.98x and a peer average of 34.13x. Simply Wall St’s Fair Ratio for Omnicell is 35.27x. The Fair Ratio is a proprietary estimate of what the P/E might be given factors such as earnings growth, profit margins, industry, market cap and risk profile. That makes it a more tailored benchmark than a simple comparison with broad industry or peer averages.

Since Omnicell’s actual P/E of 99.54x is well above the Fair Ratio of 35.27x, the stock screens as expensive on this metric.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Omnicell Narrative

Earlier it was mentioned that there is an even better way to think about valuation. This is where Narratives come in, giving you a simple story that connects your view on Omnicell’s business to a set of revenue, earnings and margin assumptions, then into a Fair Value that you can compare to today’s price.

On Simply Wall St’s Community page, Narratives are easy to use. They let you start from the numbers, add your own view on how Omnicell’s cabinet replacement cycle, SaaS transition or cost pressures might play out, and immediately see how that translates into a Fair Value estimate.

Because Narratives update when new information such as earnings, guidance or news is added, you can quickly see whether your Fair Value still supports buying, holding or taking profits, based on the gap between your Fair Value and the current share price.

For Omnicell, one investor might align with a more optimistic Narrative that points to a Fair Value around US$63 per share. Another might prefer a more cautious Narrative closer to US$55. Seeing those side by side helps you decide which story and set of assumptions fits your own view before acting.

Do you think there's more to the story for Omnicell? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.